ライフサイエンスコーパス: TGF-beta type I receptor

1 of activin receptor-like kinase (ALK)5 (the TGF-beta type I receptor).

2 of the adaptor protein ShcA by the activated TGF-beta type I receptor.

3 3, a key signal transducer downstream of the TGF-beta type I receptor.

4 rylation of Smad2 and Smad3 by the activated TGF-beta type I receptor.

5 cer cells expressing a constitutively active TGF-beta type I receptor.

6 ycin-induced dissociation of FKBP12 from the TGF-beta type I receptor.

7 we directly monitored internalization of the TGF-beta type I receptor.

8 ession induced by Smads as well as activated TGF-beta type I receptors.

9 and to the transforming growth factor beta (TGF-beta) type I receptor.

10 Inhibiting the activity or expression of the TGF-beta type I receptor abrogated collagen-induced Snai

11 64RAD) and a small molecule inhibitor of the TGF-beta type I receptor activin-like kinase (ALK5) (SB4

12 We expressed the kinase domain of the TGF-beta type I receptor [activin receptor-like kinase (

13 d3(+/+) or Smad3(-/-) mice revealed that the TGF-beta type I receptor (ALK-5) and its intracellular s

14 The TGF-beta-Type I receptor (ALK-5) antagonist SB431542 and

15 Here we show that putative Tgf-beta type I receptors, Alk-1, Alk-2, and Alk-5, are

16 SB431542 (SB43), a specific inhibitor of the TGF-beta type I receptor Alk4/5/7.

17 ting mice with a conditional knockout of the TGF-beta type I receptor ALK5 (ALK5(CKO)) in skeletal pr

18 This inhibitory effect requires the TGF-beta type I receptor ALK5 and is independent of new

19 In this study, we have ablated the Tgf-beta type I receptor Alk5 in endo-, myo- and epicard

20 with TGF-beta or expression of an activated TGF-beta type I receptor (Alk5 with the mutation T204D [

21 Expression of a constitutively active TGF-beta type I receptor (ALK5(T204D)) induced motility

22 -beta signaling with a constitutively active TGF-beta type I receptor (ALK5(TD)) but not by reconstit

23 eptor appears to bind only TGF-beta, whereas TGF-beta type I receptor (ALK5) also binds to ligands in

24 We show that the loss of the TGF-beta type I receptor (Alk5) in the cranial neural cr

25 r FKBP12-resistant and constitutively active TGF-beta type I receptor (ALK5), we demonstrate that mam

26 This study investigated the role of TGF-beta type I receptor, ALK5, and three mitogen-activa

27 cultured endothelial cells, ALK1 and another TGF-beta type I receptor, ALK5, regulate angiogenesis by

28 ype II receptor (Wnt1-Cre;Tgfbr2(fl/fl)) and TGF-beta type I receptor/Alk5 (Wnt1-Cre;Alk5(fl)(/fl)) c

29 lass of 4-pyridinoxy-2-anilinopyridine-based TGF-beta type I receptor (also known as activin-like kin

30 g to attenuate recruitment of Smad2/3 to the TGF-beta type I receptor (also termed activin receptor-l

31 Smad proteins are substrates of the TGF-beta type I receptor and are responsible for transdu

32 rotein, resulting in increased levels of the TGF-beta type I receptor and downstream activation of TG

33 d Panc-1 cells correlates with low levels of TGF-beta type I receptor and results in an altered expre

34 ta secretion, activating fibroblasts through TGF-beta type I receptors and Smad3 phosphorylation.

35 1 (ALK1), a transforming growth factor beta (TGF-beta) type I receptor, and endoglin, a TGF-beta co-r

36 Treatment with a pharmacological TGF-beta type I receptor antagonist suppressed TGF-beta

37 onstructs along with a constitutively active TGF-beta type I receptor construct identified functional

38 This clone shares some homology with the TGF-beta type I receptor family, but lacks the intracell

39 FKBP12 binds to ligand-free TGF beta type I receptor, from which it is released upon

40 We report somatic alterations of the TGF-beta type I receptor gene ALK-5.

41 Here, we deleted the TGF-beta type I receptor gene Alk5 specifically in the e

42 The rat TGF-beta type I receptor gene promoter contains cis-acti

43 not change in chromatin associated with the TGF-beta type I receptor gene.

44 ally xIAP (i) interacted physically with the TGF-beta type I receptor, (ii) mediated the ubiquitinati

45 ade by expression of a constitutively active TGF-beta type I receptor in the breast cancer cells incr

46 Treatment with a TGF-beta type I receptor inhibitor partially rescued the

47 enocyte death, which can be prevented by the TGF-beta type I receptor inhibitor SD208.

48 negative TGF-beta type II receptor, use of a TGF-beta type I receptor inhibitor, or ectopic expressio

49 Our data indicate that TGF-beta type I receptor is endocytosed via a clathrin-d

50 his study, we investigated the efficacy of a TGF-beta type I receptor kinase inhibitor (TbetaRI-I) to

51 Smad4 or blocking TGF-beta signaling with a TGF-beta type I receptor kinase inhibitor in Smad4-intac

52 The TGF-beta type I receptor kinase inhibitor LY2157299, a n

53 herapies with TGF-beta suppression using the TGF-beta type I receptor kinase inhibitor SM16.

54 t the C-terminal SSXS motif by the activated TGF-beta type I receptor kinase triggers a conformation

55 with LY364947, a small-molecule inhibitor of TGF-beta type I receptor kinase, before irradiation.

56 tors of the transforming growth factor-beta (TGF-beta) type I receptor kinase as a potential therapy

57 vity for ALK2 versus closely related BMP and TGF-beta type I receptor kinases.

58 to TGF-beta and which express a low level of TGF-beta type I receptor mRNA relative to a gastric canc

59 examined and induced TbetaRII mRNA, but not TGF-beta type I receptor mRNA.

60 crease in the expression and activity of the TGF-beta type I receptor on matrix-producing bone cells.

61 TGF beta signaling by stably associating to TGF beta type I receptors or, as it was shown for Smad6,

62 We generated mice expressing an activated TGF-beta type I receptor or dominant negative TGF-beta t

63 g the kinase domain of ALK-1 with either the TGF-beta type I receptor or the activin type IB receptor

64 utation (DR26Delta25), which is deficient in TGF-beta type I receptor recruitment to the ligand, indu

65 mutant, constitutively activated form of the Tgf-beta type I receptor repressed Sp-B promoter activit

66 hereas expression of a constitutively active TGF-beta type I receptor rescues it.

67 by stable expression of a mutant form of the TGF-beta type I receptor (RImL45) unable to bind Smad2/3

68 idazole inhibitors of p38, which inhibit the TGF-beta type I receptor serine/threonine kinase known a

69 two lung fibroblast cell lines expressed the TGF-beta type I receptor (T beta RI) and type II recepto

70 ghly restricted subset of receptors known as TGF-beta type I receptor (TbetaR-I) and TGF-beta type II

71 3 gene and LM-332 protein expression via the TGF-beta type I receptor (TbetaR-I) and the Smad2-Smad4

72 The L45 sequence of the TGF-beta type I receptor (TbetaR-I) specifies Smad2 inte

73 o the loss of cell surface expression of the TGF-beta type I receptor (TbetaR-I).

74 In this work, we identify the TGF-beta type I receptor (TbetaRI) as a target of Six1 a

75 a structural motif essential for binding the TGF-beta type I receptor (TbetaRI) but dispensable for b

76 a neutralizing antibody or inhibitors of the TGF-beta type I receptor (TbetaRI) or Smad3 eliminated t

77 hat upon TGF-beta stimulation, the activated TGF-beta type I receptor (TbetaRI) recruits and directly

78 TGF-beta type-I receptor (TbetaRI) is the major receptor

79 n, and this upregulation was suppressed by a TGF-beta type I receptor (TGFbetaR-I) inhibitor.

80 ne encoding transforming growth factor-beta (TGF-beta) type I receptor, TGFBR1, is a quantitative tra

81 in the immunohistochemical expression of the TGF-beta type I receptor, the epidermal expression of th

82 that the immunophilin FKBP12 interacts with TGF-beta type I receptors, the role of FKBP12 in TGF-bet

83 ted by TGF-beta 1 or a constitutively active TGF-beta type I receptor via TGF-beta-specific Smad prot

84 lls, the expression of constitutively active TGF-beta type I receptor was able to induce the formatio

85 ic context-dependent, as hyperactivating the TGF-beta type I receptor without PTEN deficiency and Bra